Repare Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Repare Therapeutics Inc. |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Repare Therapeutics filed its Q1 2025 10-Q, showing financial and operational updates.
AI Summary
Repare Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business segment information are presented, reflecting the company's ongoing development activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and stakeholders with the latest financial health and operational status of Repare Therapeutics, crucial for understanding its progress in drug development.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Repare Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 — Quarterly Period (Reporting period is the first quarter of 2025.)
Key Players & Entities
- Repare Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date
- 001-39335 (dollar_amount) — SEC File Number
FAQ
What is the primary business of Repare Therapeutics Inc.?
Repare Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the fiscal year end for Repare Therapeutics Inc.?
The fiscal year end for Repare Therapeutics Inc. is December 31.
What is the filing date of this 10-Q report?
The filing date of this 10-Q report is May 13, 2025.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
What is the SEC file number for Repare Therapeutics Inc.?
The SEC file number for Repare Therapeutics Inc. is 001-39335.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Repare Therapeutics Inc..